Ankur K. Nagaraja

2.8k total citations · 1 hit paper
18 papers, 1.8k citations indexed

About

Ankur K. Nagaraja is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ankur K. Nagaraja has authored 18 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Cancer Research and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ankur K. Nagaraja's work include MicroRNA in disease regulation (6 papers), Circular RNAs in diseases (4 papers) and Cancer-related molecular mechanisms research (4 papers). Ankur K. Nagaraja is often cited by papers focused on MicroRNA in disease regulation (6 papers), Circular RNAs in diseases (4 papers) and Cancer-related molecular mechanisms research (4 papers). Ankur K. Nagaraja collaborates with scholars based in United States, China and Japan. Ankur K. Nagaraja's co-authors include Martin M. Matzuk, Mark A. Edson, Preethi H. Gunaratne, Chad J. Creighton, Huifeng Zhu, Matthew L. Anderson, Julio E. Agno, Emuejevoke Olokpa, Zhifeng Yu and Samir Hanash and has published in prestigious journals such as Nature Communications, Genes & Development and PLoS ONE.

In The Last Decade

Ankur K. Nagaraja

16 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Mammalian Ovary from Genesis to Revelation

2009 577 citations Mark A. Edson, Ankur K. Nagaraja et al. Endocrine Reviews profile →

Peers

Countries citing papers authored by Ankur K. Nagaraja

Since Specialization

Citations

This map shows the geographic impact of Ankur K. Nagaraja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ankur K. Nagaraja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ankur K. Nagaraja more than expected).

Fields of papers citing papers by Ankur K. Nagaraja

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ankur K. Nagaraja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ankur K. Nagaraja. The network helps show where Ankur K. Nagaraja may publish in the future.

Co-authorship network of co-authors of Ankur K. Nagaraja

This figure shows the co-authorship network connecting the top 25 collaborators of Ankur K. Nagaraja. A scholar is included among the top collaborators of Ankur K. Nagaraja based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ankur K. Nagaraja. Ankur K. Nagaraja is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	925MO First-in-human phase I/Ib study of the oral Werner (WRN) helicase inhibitor HRO761 in patients (pts) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors: Interim safety and efficacy analysis from HRO761 single agent dose escalation 2025 ·Annals of Oncology ·Michael B. Foote, Jingjing Li, Daniel Shao-Weng Tan, Aitana Calvo, Rachel Galot, Elena Garralda, Tormod Kyrre Guren, Antoine Italiano, (unknown), Zev A. Wainberg, Jeffrey Yachnin, Timothy A. Yap, Ruben de Kanter, Nuno Grande, (unknown), Dragana Janković, Laurent Sansregret, Chao Zhang, Ankur K. Nagaraja, Yasutoshi Kuboki	0
2	Abstract 2834: CyclinE1 amplification promotes chromosomal instability and distinct vulnerabilities in gastroesophageal adenocarcinoma 2025 ·Cancer Research ·Zhong Wu, Ankur K. Nagaraja, (unknown), Lan Ling, Jin Zhou, Adam J. Bass	0
3	Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma 2021 ·Gut ·Jin Zhou, Zhong Wu, Zhouwei Zhang, (unknown), James M. McFarland, Ankur K. Nagaraja, Yingtian Xie, Shengqing Gu, Ke Peng, Yong Zeng, Xiaoyang Zhang, Henry W. Long, Hiroshi Nakagawa, Anil K. Rustgi, J. Alan Diehl, Matthew Meyerson, Kwok‐Kin Wong, Adam J. Bass	20
4	Transcription factor-mediated intestinal metaplasia and the role of a shadow enhancer 2021 ·Genes & Development ·Harshabad Singh, Davide Seruggia, Shariq Madha, Madhurima Saxena, Ankur K. Nagaraja, Zhong Wu, Jin Zhou, Aaron J. Huebner, (unknown), (unknown), Konrad Hochedlinger, Stuart H. Orkin, Adam J. Bass, Jason L. Hornick, Ramesh A. Shivdasani	14
5	Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma 2019 ·Cancer Discovery ·Ankur K. Nagaraja, Osamu Kikuchi, Adam J. Bass	37
6	CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma 2017 ·Nature Communications ·Jin Zhou, Zhong Wu, Gabrielle S. Wong, Eirini Pectasides, Ankur K. Nagaraja, Matthew D. Stachler, Haikuo Zhang, Ting Chen, Haisheng Zhang, Jie Bin Liu, Xinsen Xu, Ewa Sicińska, Francisco Sánchez-Vega, Anil K. Rustgi, J. Alan Diehl, Kwok‐Kin Wong, Adam J. Bass	64
7	Transforming Growth Factor β Receptor Type 1 Is Essential for Female Reproductive Tract Integrity and Function 2011 ·PLoS Genetics ·Qinglei Li, Julio E. Agno, Mark A. Edson, Ankur K. Nagaraja, Takashi Nagashima, Martin M. Matzuk	88
8	Molecular Profiling Uncovers a p53-Associated Role for MicroRNA-31 in Inhibiting the Proliferation of Serous Ovarian Carcinomas and Other Cancers 2010 ·Cancer Research ·Chad J. Creighton, Michael D. Fountain, Zhifeng Yu, Ankur K. Nagaraja, Huifeng Zhu, (unknown), Emuejevoke Olokpa, Azam Zariff, Preethi H. Gunaratne, Martin M. Matzuk, Matthew L. Anderson	217
9	Discovery of Novel MicroRNAs in Female Reproductive Tract Using Next Generation Sequencing 2010 ·PLoS ONE ·Chad J. Creighton, Ashley Benham, Huifeng Zhu, (unknown), Jeffrey G. Reid, Ankur K. Nagaraja, Michael D. Fountain, (unknown), (unknown), Lang Ma, Jong Kim, Shannon M. Hawkins, Matthew L. Anderson, Martin M. Matzuk, Preethi H. Gunaratne	76
10	Defective Gonadotropin-Dependent Ovarian Folliculogenesis and Granulosa Cell Gene Expression in Inhibin-Deficient Mice 2010 ·Endocrinology ·Ankur K. Nagaraja, Brooke Middlebrook, Saneal Rajanahally, Michelle Myers, Qinglei Li, Martin M. Matzuk, Stephanie A. Pangas	24
11	A Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian Cancer 2010 ·Molecular Endocrinology ·Ankur K. Nagaraja, Chad J. Creighton, Zhifeng Yu, Huifeng Zhu, Preethi H. Gunaratne, Jeffrey G. Reid, Emuejevoke Olokpa, Hiroaki Itamochi, Naoto T. Ueno, Shannon M. Hawkins, Matthew L. Anderson, Martin M. Matzuk	197
12	MiR-31 Is a Tumor Suppressor MicroRNA That Functions in Ovarian Cancer. 2010 ·Biology of Reproduction ·Zhifeng Yu, Chad J. Creighton, Michael D. Fountain, Ankur K. Nagaraja, Huifeng Zhu, (unknown), (unknown), Emuejevoke Olokpa, Shannon M. Hawkins, Preethi H. Gunaratne, Matthew L. Anderson, Martin M. Matzuk	2
13	Developmentally regulated SMAD2 and SMAD3 utilization directs activin signaling outcomes 2009 ·Developmental Dynamics ·Catherine Itman, Chris Small, Michael D. Griswold, Ankur K. Nagaraja, Martin M. Matzuk, Chester Brown, David A. Jans, Kate L. Loveland	40
14	The Mammalian Ovary from Genesis to Revelation breakdown → 2009 ·Endocrine Reviews ·Mark A. Edson, Ankur K. Nagaraja, Martin M. Matzuk	577
15	Mouse let-7 miRNA populations exhibit RNA editing that is constrained in the 5′-seed/ cleavage/anchor regions and stabilize predicted mmu-let-7a:mRNA duplexes 2008 ·Genome Research ·Jeffrey G. Reid, Ankur K. Nagaraja, Francis C. Lynn, Rafal Drabek, Donna M. Muzny, Chad A. Shaw, (unknown), A.O. Naghavi, (unknown), Huifeng Zhu, Jayantha B. Tennakoon, Gemunu H. Gunaratne, David B. Corry, Jonathan Miller, Michael T. McManus, Michael S. German, Richard A. Gibbs, Martin M. Matzuk, Preethi H. Gunaratne	73
16	Luteinizing hormone promotes gonadal tumorigenesis in inhibin-deficient mice 2008 ·Molecular and Cellular Endocrinology ·Ankur K. Nagaraja, Julio E. Agno, T. Rajendra Kumar, Martin M. Matzuk	17
17	A bioinformatics tool for linking gene expression profiling results with public databases of microRNA target predictions 2008 ·RNA ·Chad J. Creighton, Ankur K. Nagaraja, Samir Hanash, Martin M. Matzuk, Preethi H. Gunaratne	132
18	Deletion of Dicer in Somatic Cells of the Female Reproductive Tract Causes Sterility 2008 ·Molecular Endocrinology ·Ankur K. Nagaraja, Claudia Andreu‐Vieyra, Heather L. Franco, Lang Ma, Ruihong Chen, (unknown), Huifeng Zhu, Julio E. Agno, Preethi H. Gunaratne, Francesco J. DeMayo, Martin M. Matzuk	226

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact